Introduction
Individuals with chronic inflammation have an increased risk of cardiovascular disease, [1] [2] [3] and some of this increased risk is mediated by the development of increased insulin resistance and diabetes mellitus (DM). 4, 5 More specifically, cardiovascular disease is a major cause of death in patients with rheumatoid arthritis (RA), 6 and individuals with RA or psoriasis (PS) have an increased risk of insulin resistance and DM.
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Chen et al insulin resistance and DM. 11, 12 TNF inhibitors, such as etanercept (ETN) and adalimumab (ADA), may be prescribed to patients with RA, PS and psoriatic arthritis (PSA), and other autoimmune diseases. Thus, it seems possible that patients given an anti-TNF drug for treatment of an autoimmune disease may also benefit by having delayed development of DM and reduced risk of cardiovascular disease. In fact, a recent study of RA patients reported that patients who used a TNF inhibitor had a reduced risk of DM. 13 These results are in line with the in vitro study by Zhou et al, 14 who studied cultured human adipocytes and concluded that TNF increases the sensitivity of adipocytes to insulin.
Hydroxychloroquine (HCQ) is best known as a traditional treatment for malaria, but is also indicated for patients with RA and SLE. HCQ may also inhibit the development of insulin resistance and DM in patients with RA and PS. [15] [16] [17] The mechanism of action of HCQ in the prevention of insulin resistance and DM is not completely resolved, but may involve blocking of toll-like receptors 7 and 9 and inhibition of the production of interferon-α. 18 To the best of our knowledge, no study has yet examined the association between the use of a disease-modifying antirheumatic drug (DMARD) and the risk of DM in a nationwide cohort of patients with ankylosing spondylitis (AS), RA, and PS/PSA. This study used the Taiwanese National Health Insurance Research Database (NHIRD) to estimate the risk of incident DM in a nationwide cohort of patients who initiated treatment with an anti-TNF agent, cyclosporine (CSA), HCQ, or another nonbiologic DMARD for RA, PS/PSA, or AS.
Patients and methods study design, data source, and patient selection
This was a retrospective cohort study that used data from the National Health Insurance (NHI) program of Taiwan, which covers more than 99% of the population. The National Health Research Institute (NHRI) manages the NHIRD and releases claims data of ambulatory care, inpatient services, dental services, traditional Chinese medical services, and prescription drug use for research purposes. All data were encrypted to ensure anonymity before being sent to the NHRI, and data that may enable identification of individuals were removed before release to researchers. Some individual information, such as use of tobacco and alcohol, examination data, and family history of DM, are not included in the NHIRD. To improve the accuracy of coding, the Bureau of NHI routinely performs random checks of patient charts to ensure coding validity. 19 The present study utilized ambulatory, inpatient, and enrollment claims data from the NHIRD for the period [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] 
DMaRD use in Taiwan
Based on a review of the NHIRD, the commonly used drugs (in the order of frequency) for AS are nonsteroidal antiinflammatory drugs (NSAIDs), salazopyrine, corticosteroid, anti-TNF agent, and HCQ; those used for RA are NSAIDs, corticosteroid, MTX, salazopyrine, LEF, anti-TNF agent, CSA, and AZA; those used for PS are MTX, CSA, LEF, salazopyrine, and anti-TNF agent; and those used for PSA are NSAIDs, corticosteroid, MTX, LEF, salazopyrine, and anti-TNF agent. Anti-TNF therapy is currently a second-line treatment in Taiwan 
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DMaRDs and DM in as, Ra, or Psa treatment according to the NHIA guideline, 20 which is based on the National Institute for Health and Care Excellence guideline 21 but with slight modification.
index dates
The drug index date was defined as the first date of observation of AS, RA, or PS/PSA from an ambulatory visit at which a prescription for an anti-TNF agent or a traditional synthetic DMARD was given. The DM index date was the date on which there was a diagnosis of DM (ICD9-CM code 250.X), which includes type-1 and type-2 DM, and concurrent prescription of an anti-diabetes medication for more than 28 days after January 1, 2001. Characteristics of enrolled patients Table 1 summarizes the characteristics of patients in these 4 groups. Patients in the reference group (mean age: 39.0 years) were significantly younger than those in the other groups (anti-TNF: 49.2 years, CSA: 48.0 years, HCQ: 50.5 years). Most patients in the anti-TNF, CSA, and HCQ groups were female (66.7%-72.6%), but most of the patients in the reference group were male (67.3%). Most patients in the anti-TNF, CSA, and HCQ groups had RA (72.9%-78.9%), but most patients in the reference group had AS (61.8%) or PS/PSA (26.0%). Most subjects in the CSA, HCQ, and reference groups had a disease duration less than 5 years (77.2%-88.9%), but only 38.2% of subjects in the anti-TNF group had a disease duration less than 5 years. Most patients in the anti-TNF and CSA groups had pretreatment CCI scores of 1-4 (79.5% and 77.3%, respectively), most patients in the HCQ group had CCI scores of 0-1 (76.6%), and most patients in the reference group had CCI scores of 0 (73.8%). Analysis of the pretreatment use of prednisoloneequivalents within 1 year indicated that most patients in the anti-TNF group (69.7%) and CSA group (64.2%) took more than 1 mg/day, and most patients in the HCQ group (80.1%) and reference group (92.2%) took no more than 1 mg/day. There were significantly fewer overall patients in the reference group who used MTX (n=13,893, 31.1%, P,0.001), but significantly more patients in the reference group with AS who used MTX (n=3,159, 22.7%, P,0.001).
Outcome variables and potential confounders
incidence of DM in patients who used different DMaRDs Table 2 shows the incidence of newly diagnosed DM in each of the 4 groups. There were 127 cases of DM in the anti-TNF group, 26 in the CSA group, 1,000 in the HCQ group, and 1,486 in the reference group. The CSA group had the Figure 1A shows the cumulative incidence of DM in each of these 4 groups. These results show that the anti-TNF group had a significantly lower cumulative incidence of DM than the CSA group (P=0.014). The HCQ and reference groups also had significantly lower cumulative incidences of DM than the CSA group (P=0.022 and P=0.013, respectively).
We further categorized anti-TNF users as those who did and did not use HCQ ( Figure 1B ). This analysis showed that there was no protective effect of using an anti-TNF agent when HCQ was not used concomitantly. In particular, the cumulative DM incidence in the group that used anti-TNF without HCQ was comparable to that of the CSA group, and b Daily average-equivalent dose in the 1 year before the index date. Abbreviations: as, ankylosing spondylitis; Ra, rheumatoid arthritis; Ps/Psa, psoriasis/psoriatic arthritis; DMaRD, disease-modifying antirheumatic drug; TnF, tumor necrosis factor; Csa, cyclosporine; hCQ, hydroxychloroquine; CCi, Charlson comorbidity index; MTX, methotrexate. 
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DMaRDs and DM in as, Ra, or Psa significantly higher than the other 3 groups (P#0.001 for all comparisons). The protective effect of using an anti-TNF agent remained significant in the anti-TNF + HCQ group, and this group had a lower cumulative incidence of DM than all other groups (vs anti-TNF without HCQ: P,0.001; vs CSA: P,0.001; vs HCQ: P=0.015; vs reference group: P=0.031). Table 3 summarizes the risk factors for DM in our population. The univariate analysis indicated that the following factors were associated with an increased risk of DM: advanced age, PA/PSA and RA rather than AS, longer disease duration (.5-10 years vs #5 years), higher pretreatment CCI score, and pretreatment use of prednisolone. In addition, relative to the use of reference therapy, use of an anti-TNF agent with HCQ had a significant protective effect, whereas the use of an anti-TNF agent alone and use of CSA increased the risk of DM. Table 3 also shows the results of the multivariable analysis of the risk of DM. These results show that the following factors were independently associated with an increased risk of DM: advanced age (aHR: 1.04, P,0.001), PS/PSA rather than AS (aHR: 2.44, P,0.001), pretreatment CCI score of 2-4 (aHR: 1.29, P,0.001) or 5 or more (aHR: 1.38, P=0.006) rather than CCI score of 0, and pretreatment use of prednisolone at 1 mg/day or less (aHR: 1.26, P,0.001) or more than 1 mg/day (aHR: 1.30, P,0.001) relative to no prednisolone use. These results also show that relative to the use of the reference therapy, the use of an anti-TNF agent with HCQ (aHR: 0.49, P,0.001) and use of HCQ alone (aHR: 0.70, P,0.001) had protective effects. In addition, the use of prednisolone, MTX, SSZ, LEF, and AZA also protected against the development of DM.
Risk factors for DM
Risk factors for DM with stratification by disease duration
We further analyzed the risk of DM with stratification by disease duration ( Table 4 ). The multivariable Cox regression models showed that among those with disease durations of 5 years or less and 5-10 years, there were significant associations of advanced age, PS/PSA, and higher pretreatment CCI score with DM. The association of pretreatment prednisolone use with DM occurred in those with a disease duration of 5 years or less, but not in those with disease durations of 5-10 years and more than 10 years. Relative to the reference treatment, anti-TNF + HCQ therapy was protective in those with disease durations of 5 years or less (aHR: 0.56, P=0.003) and 5-10 years (aHR: 0.33, P,0.001); HCQ therapy had a protective effect in those with disease durations of 5 years or less (aHR: 0.71, P,0.001), 5-10 years (aHR: 0.61, P=0.017), and more than 10 years (aHR: 0.21, P=0.040). Prednisolone, MTX, SSZ, and LEF were protective for those with a disease duration of 5 or fewer years, but provided decreasing benefit for those with disease for more than 5 years. 
013). (B)
The cumulative incidence of DM was similar in the CSA group and the group that used anti-TNF without HCQ, and significantly lower in the other 3 groups (anti-TNF + hCQ, hCQ, other DMaRDs); the cumulative incidence of DM in the anti-TnF + HCQ group was significantly lower than in the other 4 groups (vs anti-TNF without HCQ: P,0.001; (Table 5 ). This analysis showed significant associations of advanced age with DM in all 3 groups. In the AS group, males were more likely to develop DM than females (hazard ratio [HR]: 1.31, P=0.012). In the PS/PSA group, patients with a disease duration longer than 10 years were less likely to develop DM relative to those with a disease duration of 5 years or less (HR: 0.41, P,0.001).
In the AS and RA groups, patients with a high pretreatment CCI score and those who used prednisolone before treatment had an increased risk of DM. In the AS group, there were no newly diagnosed cases of DM among those given anti-TNF + HCQ therapy, and the use of other drug regimens had no significant effect on the development of DM. In the RA group, anti-TNF + HCQ therapy (HR: 0.45, P,0.001) and HCQ alone (HR: 0.66, P,0.001) had significant protective effects. In the PS/PSA group, HCQ had a significant protective effect (HR: 0.66, P=0.004).
Discussion
This study is the first population-based cohort study to examine the association between the use of different DMARDs and DM among patients with AS, RA, or PS/PSA. Our major finding is that the risk of DM was lowest for patients with RA or PS/PSA who initiated treatment with an anti-TNF agent and concomitant HCQ, followed by those Daily average-equivalent dose in the 1 year before the index date. *P,0.05 indicates a significant association with DM. Abbreviations: HR, hazard ratio; DM, diabetes mellitus; CI, confidence interval; AS, ankylosing spondylitis; RA, rheumatoid arthritis; PS/PSA, psoriasis/psoriatic arthritis; CCi, Charlson comorbidity index; DMaRD, disease-modifying antirheumatic drug; TnF, tumor necrosis factor; Csa, cyclosporine; hCQ, hydroxychloroquine; MTX, methotrexate; SSZ, sulfasalazine; LEF, leflunomide; AZA, azathioprine.
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DMaRDs and DM in as, Ra, or Psa who used HCQ without an anti-TNF agent. Users of anti-TNF agents without HCQ and users of other nonbiologic DMARDs had a similar risk of DM. Anti-TNF therapy and HCQ provided no benefit for patients with AS or PS/PSA. HCQ is rarely used for the treatment of PS/PSA because it may exacerbate the symptoms. 22 The finding that anti-TNF therapy alone had no effect on the development of DM might seem surprising because a previous research has indicated that anti-TNF therapy reduced insulin resistance and the risk of DM in patients with RA. 13 These apparently discrepant findings may be explained by the differences of ethnic groups, the criteria used for patient selection, and history of prednisolone usage. In addition, the protective effect of prednisolone on the development of DM is also unexpected because steroids may exacerbate DM.
A major strength of this study is that we used a nationwide population sample of Taiwanese men and women, most of whom are of Han Chinese ancestry. This design reduced selection bias, so we believe that the results are applicable to the general population of Taiwan. Another advantage of the present study relative to previous studies is that we adjusted for corticosteroid dosage, and did not simply classify patients as users and nonusers. Corticosteroids are indicated for patients with autoimmune diseases, especially PS and PSA, 23 and it is well known that they can increase insulin resistance and promote the development of DM. 24 Research that does not adjust for steroid dose may therefore overestimate the protective effect of anti-TNF agents because patients given anti-TNF agents may require lower doses of steroids. 25 In agreement with our results, previous studies have also reported that HCQ can improve insulin tolerance or reduce the incidence of DM. 26, 27 Based on studies of an animal model, HCQ appears to directly affect the pancreas, leading to elevated blood insulin and reduced blood glucose. 
Limitations
Nonetheless, there were some limitations in this study. First, DM diagnoses were based on an administrative database, and therefore should have high accuracy. However, such non-differential misclassification is always biased toward the null, so this would not change the nature of the relationships we found, but only their significance. Second, the accuracy of diagnoses of AS and PS/PSA may be a concern, as is the diagnosis of nearly all autoimmune disorders. However, our RA diagnosis is not a concern because the certification of catastrophic illness requires validation by 2 or more rheumatologists and a comprehensive review of the patients' clinical data. Another limitation is that in examining the relationship of use of DMARDs with DM, the pathologies may differ for patients receiving different treatments. The lack of information on disease activity, functional disability, and structural damage means that we could not adjust for confounding by these factors in the statistical analysis. Finally, our administrative database does not provide laboratory or clinical information on disease severity. The disease duration was the time from date of diagnosis to date of initiating a DMARD. Therefore, those who initiated a DMARD earlier may have had a greater disease activity or severity. Disease severity may be related to the risk of DM, but was not available in the database.
Conclusion
We performed a nationwide survey to examine the association between the use of different DMARD therapies and the development of DM in patients diagnosed with AS, RA, or PS/PSA. The results indicated that the risk of DM was 
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DMaRDs and DM in as, Ra, or Psa significantly lower in patients with RA or PS/PSA who initiated treatment with an anti-TNF agent with concomitant HCQ and was also lower in those who used HCQ but no anti-TNF agent. Users of anti-TNF agents without HCQ and users of other nonbiologic DMARDs had a similar risk of DM.
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